Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08OES
|
|||
| Former ID |
DNCL002513
|
|||
| Drug Name |
NiCord
|
|||
| Synonyms |
NiCord (TN)
Click to Show/Hide
|
|||
| Indication | Hematologic tumour [ICD-11: 2B33.Y] | Phase 3 | [1] | |
| Acute lymphoblastic leukaemia [ICD-11: 2A85; ICD-10: C85.1, C88.7] | Phase 1/2 | [2] | ||
| Hodgkin lymphoma [ICD-11: 2B30; ICD-10: C81, C81.9] | Phase 1/2 | [2] | ||
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 1/2 | [2] | ||
| Sickle-cell anaemia [ICD-11: 3A51; ICD-10: D57.1] | Phase 1/2 | [3] | ||
| Company |
Gamida Cell
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02730299) Stem Cell Transplantation With NiCord (Omidubicel) vs Standard Umbilical Cord Blood in Patients With Leukemia, Lymphoma, and Myelodysplastic Syndrome (MDS). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT01590628) Pilot Study Evaluating Safety & Efficacy of a DCBT: NiCord & UNM CBU to SCD Patients After Myeloablative Therapy. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.